Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8252W HIGH $9.34
Volume
284.05 K
Value Traded
3.11 M
Short % Float
8.34%
Days to Cover
7.1
-1.49%Week
-0.41%1 Month
+5.35%3 Month
+28.17%6 Month
-81.09%5 Year
-84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
481.54 M
EPS (TTM)
-0.99
P/E Ratio
-
Ent. Value
168.01 M
Total Shares
37.83 M
Float Shares
32.69 M
Insiders
20.91%
Institutions
67.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MASS Catalyst Timeline
Dated clinical, regulatory and corporate events for 908 Devices Inc.
Past FDA Catalysts and PDUFA Decisions
How MASS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
908 Devices Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MASS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brown Christopher D.Director | Sell | -30,000 745,559 held | $11.89 | 10/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MASS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.1 % | 879.22 K | 100.37 K | 0.37% ( 368.00) |
MASS Institutional Ownership Trends
MASS Short Interest
Shares sold short, counted twice a month.
8.34%
Short % of Float
of tradable shares sold short
2.7M
Shares Sold Short
-0.7% vs prior count
7.1 High
Days to Cover
trading days of normal volume to buy every short share back
380.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MASS ranks across every disease it competes in
Competitive Position is a premium feature
See how MASS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMASS News
MASS▲ +1.4%today
908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
908 Devices Inc. will report its third quarter 2026 financial results on November 10, 2026. The report will be released before the market opens, followed by a conference call at 8:30 a.m. ET. The company specializes in handheld chemical analysis tools for health, safety, and defense applications.
Read more →MASS908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
908 Devices Inc. will present at the 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City. The company's management is scheduled to present at 3:45 p.m. ET, with a webcast available for interested parties. Their handheld devices are designed for critical applications in health, safety, and defense.
Read more →MASS908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
908 Devices Inc. will present at the 17th Annual Midwest IDEAS Investor Conference on August 26, 2026. CEO Kevin J. Knopp and CFO Joe Griffith will host investor meetings and the presentation will be accessible via webcast. The company focuses on handheld chemical analysis tools for health, safety, and defense applications.
Read more →MASS▲ +13.7%on this newsshared move
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
908 Devices Inc. reported a 23% increase in revenue for Q2 2026, reaching $16.1 million. The company narrowed its Adjusted EBITDA loss significantly compared to the previous year, demonstrating strong performance, particularly with its VipIR product. The updated revenue outlook for 2026 reflects expected growth of 21% to 25%. Despite these positives, the company continues to face substantial net losses.
Read more →MASS▲ +8.1%on this news· ran to +20% by day 3
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
908 Devices Inc. will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12. The company's management is set to present at 12:30 p.m. Eastern Time. Interested parties can access the presentation via a live and archived webcast on their website. 908 Devices specializes in handheld chemical analysis tools for health, safety, and defense applications.
Read more →MASS908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026
908 Devices Inc. will report its financial results for the second quarter of 2026 on August 11, 2026, before market opening. The company specializes in handheld chemical analysis tools for health, safety, and defense applications. A conference call will follow the report, allowing investors to gain insights into the company's performance.
Read more →MASS908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
908 Devices Inc. has announced the granting of stock options to four new non-executive employees as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The options, totaling 179,912 shares, have an exercise price of $8.63 per share and will vest over four years. This initiative aims to enhance the company's workforce and support its growth in chemical analysis technology.
Read more →MASS▲ +9.4%on this newsshared move
908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference
908 Devices Inc. will present at the 16th Annual East Coast IDEAS Investor Conference on June 10, 2026. CEO Kevin J. Knopp and CFO Joe Griffith will host investor meetings and the presentation will be webcast. The company specializes in handheld chemical analysis tools for health, safety, and defense applications.
Read more →MASS▲ +13.7%on this news
908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio
908 Devices has acquired NIRLAB AG, enhancing its narcotics detection portfolio. The acquisition introduces AI-powered, cloud-connected near-infrared spectroscopy for rapid chemical analysis of drugs. NIRLAB's handheld device can identify over 400 substances and quantify drug purity. This strategic move aims to strengthen 908 Devices' position in law enforcement applications.
Read more →MASS▲ +13.7%on this news
908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook
908 Devices Inc. reported a strong start to 2026 with a 14% revenue growth, reaching $13.4 million for the first quarter. The company also announced the acquisition of NIRLAB AG, which is expected to enhance its capabilities in the narcotics detection market. Despite these positive results, the company faced a net loss of $12.0 million, an increase from the previous year. The outlook for 2026 has been raised, projecting revenues between $67.0 million and $70.0 million.
Read more →MASS908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026
908 Devices Inc. (Nasdaq: MASS) will report its financial results for Q1 2026 on May 6, 2026, before market open. A conference call will follow at 8:30 a.m. ET, which will be webcast live and archived for later access. The company specializes in handheld chemical analysis tools for health, safety, and defense applications.
Read more →MASS908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
908 Devices Inc. has appointed Kola Otitoju as its new Chief Business & Strategy Officer. This newly created role will focus on overseeing product and corporate strategy, business development, and partnership initiatives. The appointment reflects the company's aim to enhance its market presence in public health, safety, and defense-tech sectors.
Read more →MASS908 Devices to Present at the Sidoti Small Cap Conference
908 Devices Inc. will present at the Sidoti Small Cap Conference on March 18, 2026. CEO Kevin J. Knopp and CFO Joe Griffith will host investor meetings and present the company's advancements in handheld chemical analysis tools. The presentation will be available via a live audio webcast and archived on the company's website.
Read more →MASS908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
908 Devices Inc. reported strong financial results for Q4 and full year 2025, with revenues of $56.2 million, marking an 18% increase from the previous year. The company achieved positive Adjusted EBITDA and improved gross margins, while maintaining a solid cash position. Looking ahead, 908 Devices expects revenue growth of 15-20% for 2026.
Read more →MASS908 Devices to Participate in Investor Conferences in March
908 Devices Inc. (Nasdaq: MASS) announced its participation in upcoming investor conferences. The company focuses on handheld chemical analysis tools for health, safety, and defense applications. Their innovative devices are designed to provide quick answers to critical issues such as drug crises and toxic exposures. Interested parties can access webcasts of the sessions on their website.
Read more →MASS908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
908 Devices Inc. will report its financial results for Q4 and the full year 2025 on March 3, 2026. The announcement includes a conference call scheduled for 8:30 a.m. Eastern Time, which will be available via webcast. The company specializes in handheld chemical analysis tools for health and safety applications.
Read more →MASS▲ +19.2%on this news
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
908 Devices Inc. reported strong preliminary financial results for Q4 and full year 2025, with revenues of approximately $17.2 million for Q4, marking a 20% increase from the previous year. The company aims to be Adjusted EBITDA positive and has seen growth driven by federal and defense customers. CEO Kevin J. Knopp highlighted the company's transformation and positive market trends, particularly in response to the opioid crisis.
Read more →About 908 Devices Inc.
Headquarters44 THIRD AVENUE, BURLINGTON, MA, 01803
BIOPHARMAWATCH ELITE PLUS
Trade the next MASS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime